{"id":36636,"date":"2025-07-04T11:28:43","date_gmt":"2025-07-04T03:28:43","guid":{"rendered":"https:\/\/flcube.com\/?p=36636"},"modified":"2025-07-04T11:28:44","modified_gmt":"2025-07-04T03:28:44","slug":"brii-biosciences-licenses-brii-693-to-joincare-pharma-for-development-in-greater-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=36636","title":{"rendered":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China"},"content":{"rendered":"\n

China-based Brii Biosciences Ltd (HKG: 2137<\/a>) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380<\/a>) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.<\/p>\n\n\n\n

Licensing Agreement Details<\/strong>
Under the agreement, Joincare Pharma secures exclusive rights for research and development, regulatory filing, and commercialization of BRII-693 in Greater China. Brii Biosciences has received an undisclosed upfront payment and will be eligible for additional development and commercialization milestone payments. The company will also receive tiered royalties based on the net sales of the product.<\/p>\n\n\n\n

BRII-693: Targeting Multidrug-Resistant Infections<\/strong>
BRII-693 is an investigational novel synthetic lipopeptide designed to treat critically ill patients with multidrug-resistant and extensively drug-resistant (MDR\/XDR) Gram-negative bacterial infections. These infections are particularly caused by carbapenem-resistant Acinetobacter baumannii (CRAB), Pseudomonas aeruginosa (CRPA), and Enterobacteriaceae (CRE). BRII-693 has previously demonstrated favorable safety, tolerability, and pharmacokinetic profiles in Phase I studies.-Fineline Info & Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"

China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical…<\/p>\n","protected":false},"author":1,"featured_media":36639,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10,11],"tags":[30,449,1219,676,965],"class_list":["post-36636","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-deals","category-drug","tag-biotech","tag-brii-biosciences","tag-hkg-2137","tag-joincare-pharmaceutical","tag-sha-600380"],"yoast_head":"\nBrii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China - Insight, China's Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=36636\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China\" \/>\n<meta property=\"og:description\" content=\"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=36636\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China's Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2025-07-04T03:28:43+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-07-04T03:28:44+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China\",\"datePublished\":\"2025-07-04T03:28:43+00:00\",\"dateModified\":\"2025-07-04T03:28:44+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636\"},\"wordCount\":170,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0401.webp\",\"keywords\":[\"Biotech\",\"Brii Biosciences\",\"HKG: 2137\",\"Joincare Pharmaceutical\",\"SHA: 600380\"],\"articleSection\":[\"Company\",\"Deals\",\"Drug\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36636#respond\"]}],\"copyrightYear\":\"2025\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=36636\",\"name\":\"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China - Insight, China's Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0401.webp\",\"datePublished\":\"2025-07-04T03:28:43+00:00\",\"dateModified\":\"2025-07-04T03:28:44+00:00\",\"description\":\"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=36636\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0401.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2025\\\/07\\\/0401.webp\",\"width\":1080,\"height\":608,\"caption\":\"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=36636#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China - Insight, China's Pharmaceutical Industry","description":"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=36636","og_locale":"en_US","og_type":"article","og_title":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China","og_description":"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.","og_url":"https:\/\/flcube.com\/?p=36636","og_site_name":"Insight, China's Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2025-07-04T03:28:43+00:00","article_modified_time":"2025-07-04T03:28:44+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=36636#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=36636"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China","datePublished":"2025-07-04T03:28:43+00:00","dateModified":"2025-07-04T03:28:44+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=36636"},"wordCount":170,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=36636#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","keywords":["Biotech","Brii Biosciences","HKG: 2137","Joincare Pharmaceutical","SHA: 600380"],"articleSection":["Company","Deals","Drug"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=36636#respond"]}],"copyrightYear":"2025","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=36636","url":"https:\/\/flcube.com\/?p=36636","name":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China - Insight, China's Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=36636#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=36636#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","datePublished":"2025-07-04T03:28:43+00:00","dateModified":"2025-07-04T03:28:44+00:00","description":"China-based Brii Biosciences Ltd (HKG: 2137) announced a licensing agreement with compatriot firm Joincare Pharmaceutical Group Industry Co., Ltd (SHA: 600380) for its investigational drug BRII-693. This strategic partnership aims to advance the development and commercialization of BRII-693 in Greater China.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=36636#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=36636"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=36636#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","width":1080,"height":608,"caption":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=36636#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Brii Biosciences Licenses BRII-693 to Joincare Pharma for Development in Greater China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2025\/07\/0401.webp","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36636","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=36636"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36636\/revisions"}],"predecessor-version":[{"id":36640,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/36636\/revisions\/36640"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/36639"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=36636"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=36636"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=36636"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}